Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 8 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 2 Carcinoma 2 Adenocarcinoma 2 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Pancreatic Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Diffuse Intrinsic Pontine Glioma 1 Colorectal Neoplasms 1 Brain Neoplasms 1 Advanced and/or Metastatic Solid Tumours 1

Interventions

pembrolizumab 72 Cisplatin 57 Cetuximab 38 Fluorouracil 25 Nivolumab 21 Radiotherapy 20 Carboplatin 19 Paclitaxel 14 Docetaxel 11 Cyclophosphamide 9 Gefitinib 8 fludarabine 7 durvalumab 7 zalutumumab 6 atezolizumab 6 Drug Therapy 6 Bleomycin 6 epacadostat 5 cemiplimab 5 Radiotherapy, Intensity-Modulated 5 Pemetrexed 5 Ipilimumab 5 Gemcitabine 5 Afatinib 5 spartalizumab 4 Standard of Care 4 Radiation 4 Injections 4 Immune Checkpoint Inhibitors 4 Fibroblast Growth Factor 7 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Head and Neck Neoplasms × nimotuzumab × Clear all

NCT01345084 2025-03-28

NICAP

Eurofarma Laboratorios S.A.

Phase 3 Withdrawn

Carcinoma, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡